HIV dual therapy shows promiseA dual-drug regiment to treat HIV could soon be a reality, according to results presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
Single-tablet HIV drug approved by FDAFDA has approved abacavir 600 mg, dolutegravir 50 mg (Tivicay) and lamivudine 300 mg (Triumeq, ViiV Healthcare) as as a first-line therapy to treat HIV.
FDA approves new once-daily treatment option for HIVDolutegravir, a new, once-daily option, may allow improved personalization of a patient’s medication regimen.
New molecular entity: TivicayAn integrase strand transfer inhibitor for treatment of HIV 1 infection in adults and pediatric patients aged 12 years and older and weighing at least 40 kilograms, as part of combination antiretroviral therapy.
New HIV drug approvedFDA this week approved integrase strand transfer inhibitor dolutegravir (Tivicay, ViiV Healthcare , GlaxoSmithKline) to treat HIV-1 infection.